Ditchcarbon
  • Customers
  1. Organizations
  2. Apotex
Public Profile
Pharmaceutical Preparation Manufacturing
CA
updated 10 days ago

Apotex

Company website

Apotex Inc., a leading Canadian pharmaceutical company, is headquartered in Toronto, Ontario, Canada. Founded in 1974, Apotex has established itself as a key player in the global generic and specialty pharmaceuticals industry, with a strong presence in North America, Europe, and other international markets. The company is renowned for its extensive portfolio of over 300 generic medications, which are designed to provide affordable alternatives to brand-name drugs. Apotex's commitment to quality and innovation has led to significant milestones, including the development of complex generics and biosimilars. With a robust manufacturing infrastructure and a focus on research and development, Apotex has achieved a notable market position, consistently ranking among the top generic drug manufacturers in Canada and worldwide. Its dedication to improving patient access to essential medications underscores its reputation as a trusted leader in the pharmaceutical sector.

DitchCarbon Score

How does Apotex's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

37

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Apotex's score of 37 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Apotex's reported carbon emissions

In 2023, Apotex reported total carbon emissions of approximately 40,219,000 kg CO2e for Scope 1 and about 15,572,000 kg CO2e for Scope 2. This reflects a slight decrease in emissions compared to 2022, where Scope 1 emissions were about 42,950,000 kg CO2e and Scope 2 emissions were approximately 16,173,000 kg CO2e. The company has not disclosed any Scope 3 emissions data. Apotex is currently evaluating potential pathways to decarbonisation, with a focus on setting near-term emissions reduction targets for both Scope 1 and Scope 2 emissions by 2025. This initiative is part of their commitment to achieving net-zero emissions, although specific reduction percentages have not yet been established. The emissions data is cascaded from Apotex Inc., the parent company, which provides a comprehensive overview of the organisation's climate impact. Apotex's ongoing efforts to assess and implement decarbonisation strategies demonstrate their commitment to addressing climate change and reducing their carbon footprint in the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201820192020202120222023
Scope 1
44,817,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
20,870,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Apotex's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Apotex is in CA, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Apotex is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Knight Therapeutics Inc.

CA
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Akorn

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Fresenius Kabi USA, LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Perrigo

IE
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Astrazeneca Canada Inc.

CA
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

AvKARE, LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 14 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250808.10
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy